TITLE

The Industry

PUB. DATE
January 2009
SOURCE
Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers global news briefs related to pharmaceutical industry. Jazz Pharmaceuticals Inc. has reduced its sales force through eliminating 67 jobs due to the disappointing sales of its social anxiety disorder and obsessive-compulsive disorder drug. Alpharma Inc. has acquired by King Pharmaceuticals Inc. for about $1.6 billion. Solvay Pharmaceuticals Inc. has licensed exclusive rights to the Gabapentin GR (gabapentin) of Depomed Inc.
ACCESSION #
36094430

 

Related Articles

  • A Painkiller Binds Twin Pharma Deals. P., Shankar // njbiz;1/5/2009, Vol. 22 Issue 1, p2 

    The article reports on the completion of two major pharmaceutical acquisitions that center on the pain drug Kadian from Alpharma in the U.S. in December 2008. Alpharma Inc. was acquired by Bristol, Tennessee-based King Pharmaceuticals Inc. for $1.6 billion. Kadian was sold to Iceland-based...

  • Jazz Pharma Prices IPO: Nabs $108M For Luvox.  // Bioworld Week;6/11/2007, Vol. 15 Issue 24, p2 

    The article announces the initial public offering (IPO) of Jazz Pharmaceuticals Inc. The company is selling 6 million shares at $18 each. The proceeds of the sale will be used to launch an approvable Luvox CR for psychiatric disorders. Jazz Pharmaceuticals will focus on pushing to market Luvox...

  • Alpharma Stays The Course. Gaudio, Thomas // njbiz;10/20/2008, Vol. 21 Issue 43, p2 

    The article reports that specialty drug manufacturer Alpharma Inc. is not backing down from its call for shareholders to reject King Pharmaceuticals Incorporated's hostile takeover bid of $37 per share in cash as the would-be buyer extended its offer that was set to expire October 10, 2008....

  • King Plans Hostile Bid for Alpharma, Ups Offer. Young, Donna // BioWorld Today;9/12/2008, Vol. 19 Issue 178, p1 

    The article reports that King Pharmaceuticals Inc. is planning to stage a hostile take over of Alpharma Inc., by taking its offer directly to the stockholders. This development came after Alpharma has rejected King's enhanced offer to buyout the former at $37 per share. Meanwhile, Alpharma has...

  • King Plans Hostile Bid for Alpharma, Ups Offer.  // Bioworld Week;9/15/2008, Vol. 16 Issue 37, p4 

    The article reports on the plan of King Pharmaceuticals Inc. to take its offer directly to stockholders of Alpharma Inc. in Bridgewater, New Jersey. It states that Alpharma has rejected King's offer of $37 per share in August 2008. As a response, Alpharma is urging its shareholders to take no...

  • King Plans Hostile Bid for Alpharma, Ups Offer.  // Bioworld Week;9/8/2008, Vol. 16 Issue 36, p4 

    The article reports that Bridgewater, New Jersey-based Alpharma Inc. rejected an enhanced offer of $37 per share from King Pharmaceuticals Inc., which announced its intention to take its offer directly to stockholders in a hostile takeover. Alpharma rejected King's initial offer of $33 per...

  • WEEK IN REIVIEW.  // Crain's New York Business;12/1/2008, Vol. 24 Issue 48, p32 

    The article presents several news briefs from New York City. Alpharma Inc. agreed to be acquired by Tennessee drugmaker King Pharmaceuticals Inc. for $1.6 billion. The economic crisis could cost New York 225,000 jobs over the next two years. Monster Worldwide Inc. signed a deal to become the...

  • Solvay: NeoPharma acquisition would offer CNS research boost.  // PharmaWatch: CNS;Feb2005, Vol. 4 Issue 2, p4 

    The article looks into the significance of the proposed acquisition by Solvay Pharmaceuticals Inc. of NeoPharma Inc. The said acquisition will strengthen the position of Solvay Pharmaceuticals Inc. in the central nervous system research and will expand its portfolio through NeoPharma's only...

  • TOP STORIES.  // MondayMorning;10/18/2010, Vol. 18 Issue 38, p1 

    The article offers news briefs related pharmaceutical industry of the U.S. Pfizer Inc. acquires King Pharmaceuticals Inc. for 3.6 billion dollars, the deal is expected to close at the first quarter of 2011. The U.S. Food and Drug Administration (FDA) decides to revoke the approval on a patch for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics